Home » Will Dracup on Office Kick-Boxing and his Eight Years of Profitability

Will Dracup on Office Kick-Boxing and his Eight Years of Profitability

Feb 27, 2004
Premium

At A Glance

Name: Will Dracup

Position: Founder and CEO, Nonlinear Dynamics.

Background: Developer, life sciences image analysis products, Joyce Loebl, 1989.

Freelance Developer, 1984-89.

BA in economics, Manchester University, 1984.

 

Tell me about the genesis of Nonlinear Dynamics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Oct
10
Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

What's Popular?

In Proteomics & Protein Research

  1. MSK Researchers Develop High-Sensitivity Mass Spec Assay for Clinical Cancer Work

    Premium

  2. NSGC Panelists Discuss Strategies to Convert Variants of Unknown Significance to Known Significance

  3. Early Results From Second Side-Out Study Indicate Benefits of Molecularly Guided Cancer Treatment

    Premium

  4. Biognosys, Waters Ink Comarketing Deal for DIA Mass Spec Tech

  5. HMS Team Uses Protein Coregulation Analysis to Build Cancer Interactome, Predict Therapy Response

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.